Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Marcin Cyrnek"'
Autor:
Mateusz Maligłówka, Michał Kosowski, Marcin Hachuła, Marcin Cyrnek, Łukasz Bułdak, Marcin Basiak, Aleksandra Bołdys, Grzegorz Machnik, Rafał Jakub Bułdak, Bogusław Okopień
Publikováno v:
Metabolites, Vol 12, Iss 3, p 256 (2022)
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is the last discovered member of the family of proprotein convertases (PCs), mainly synthetized in hepatic cells. This serine protease plays a pivotal role in the reduction of the number of low-de
Externí odkaz:
https://doaj.org/article/f3be353381554a89a259aa08885e5fae
Autor:
Marcin Basiak, Michał Kosowski, Marcin Cyrnek, Łukasz Bułdak, Mateusz Maligłówka, Grzegorz Machnik, Bogusław Okopień
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 6, p 3144 (2021)
Proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors are a group of drugs whose main mechanism of action is binding to the PCSK-9 molecule, which reduces the degradation of the low-density lipoprotein receptor (LDL-R) and, hence, increas
Externí odkaz:
https://doaj.org/article/85847f251a1e448c88a3f052531a61b2
Autor:
Mateusz Maligłówka, Łukasz Bułdak, Marcin Cyrnek, Marcin Hachuła, Michał Kosowski, Marcin Basiak, Witold Szkróbka, Joanna Bosowska, Maciej Cebula, Michał Holecki, Bogusław Okopień
Publikováno v:
Advances in Clinical and Experimental Medicine. 32
Autor:
Mateusz Maligłówka, Łukasz Bułdak, Marcin Cyrnek, Marcin Hachuła, Michał Kosowski, Marcin Basiak, Witold Szkróbka, Joanna Bosowska, Maciej Cebula, Michał Holecki, Bogusław Okopień
Supplementary materials to the publication entitled "Initial clinical, laboratory and radiological features of COVID-19 patients and their impact on the course of the disease": Supplementary Table 1. Laboratory findings of COVID19 patients. Supplemen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e8752c670e9be8b8e863d90d3683bf9
Autor:
Michał Kosowski, Mateusz Maligłówka, Łukasz Bułdak, Marcin Cyrnek, Grzegorz Machnik, Marcin Basiak, Bogusław Okopień
Publikováno v:
International Journal of Molecular Sciences
International Journal of Molecular Sciences, Vol 22, Iss 3144, p 3144 (2021)
International Journal of Molecular Sciences, Vol 22, Iss 3144, p 3144 (2021)
Proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors are a group of drugs whose main mechanism of action is binding to the PCSK-9 molecule, which reduces the degradation of the low-density lipoprotein receptor (LDL-R) and, hence, increas